@article{1fd585486e4d4ac2b07d3820fa31c672,
title = "Association of thrombocytosis with COPD morbidity: The SPIROMICS and COPDGene cohorts",
abstract = "Background: Thrombocytosis has been associated with COPD prevalence and increased all-cause mortality in patients with acute exacerbation of COPD (AECOPD); but whether it is associated with morbidity in stable COPD is unknown. This study aims to determine the association of thrombocytosis with COPD morbidity including reported AECOPD, respiratory symptoms and exercise capacity. Methods: Participants with COPD were included from two multi-center observational studies (SPIROMICS and COPDGene). Cross-sectional associations of thrombocytosis (platelet count ≥350×109/L) with AECOPD during prior year (none vs. any), exertional dyspnea (modified Medical Research Council (mMRC) score≥2), COPD Assessment Test (CAT) score≥10, six-minute-walk distance (6MWD), and St. George Respiratory questionnaire (SGRQ) were modeled using multivariable logistic or linear regression. A pooled effect estimate for thrombocytosis was produced using meta-analysis of data from both studies. Results: Thrombocytosis was present in 124/1820 (6.8%) SPIROMICS participants and 111/2185 (5.1%) COPDGene participants. In meta-analysis thrombocytosis was associated with any AECOPD (adjusted odds ratio [aOR] 1.5; 95% confidence interval [95% CI]: 1.1-2.0), severe AECOPD (aOR 1.5; 95% CI: 1.1-2.2), dyspnea (mMRC≥2 aOR 1.4; 95% CI: 1.0-1.9), respiratory symptoms (CAT≥10 aOR 1.6; 95% CI: 1.1-2.4), and higher SGRQ score (β 2.7; 95% CI: 0.5, 5). Thrombocytosis was also associated with classification into Global Initiative for Chronic Obstructive Lung Disease (GOLD) group D (aOR 1.7 95% CI: 1.2-2.4). Conclusions: Thrombocytosis was associated with higher likelihood of prior exacerbation and worse symptoms. Platelet count, a commonly measured clinical assay, may be a biomarker for moderate-severe COPD symptoms, guide disease classification and intensity of treatment. Future longitudinal studies investigating the role of platelets in COPD progression may be warranted. Trial registration: ClinicalTrials.gov: NCT01969344(SPIROMICS) and NCT00608764(COPDGene).",
keywords = "Dyspnea, Exacerbations, Platelet count, Quality of life",
author = "{and for the SPIROMICS and COPDGene Investigators} and Ashraf Fawzy and Nirupama Putcha and Paulin, {Laura M.} and Aaron, {Carrie P.} and Labaki, {Wassim W.} and Han, {Mei Lan K.} and Wise, {Robert A.} and Kanner, {Richard E.} and Bowler, {Russell P.} and Barr, {R. Graham} and Hansel, {Nadia N.} and Alexis, {Neil E.} and Anderson, {Wayne H.} and Igor Barjaktarevic and Bleecker, {Eugene R.} and Boucher, {Richard C.} and Carretta, {Elizabeth E.} and Christenson, {Stephanie A.} and Comellas, {Alejandro P.} and Cooper, {Christopher B.} and Couper, {David J.} and Criner, {Gerard J.} and Crystal, {Ronald G.} and Curtis, {Jeffrey L.} and Doerschuk, {Claire M.} and Dransfield, {Mark T.} and Freeman, {Christine M.} and Hastie, {Annette T.} and Hoffman, {Eric A.} and Kaner, {Robert J.} and Kleerup, {Eric C.} and Krishnan, {Jerry A.} and LaVange, {Lisa M.} and Lazarus, {Stephen C.} and Martinez, {Fernando J.} and Meyers, {Deborah A.} and Moore, {Wendy C.} and Newell, {John D.} and Stephen Peters and Cheryl Pirozzi and Oelsner, {Elizabeth C.} and O'Neal, {Wanda K.} and Ortega, {Victor E.} and Robert Paine and Sanjeev Raman and Rennard, {Stephen I.} and Tashkin, {Donald P.} and Wells, {J. Michael} and Woodruff, {Prescott G.}",
note = "Funding Information: AF: NIH NHLBI T32HL007534. SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc..; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; Nycomed GmbH; Takeda Pharmaceutical Company; Novartis Pharmaceuticals Corporation; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; and Sunovion. COPDGene was supported by Award Number R01 HL089897 and Award Number R01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. Publisher Copyright: {\textcopyright} 2018 The Author(s).",
year = "2018",
month = jan,
day = "26",
doi = "10.1186/s12931-018-0717-z",
language = "English (US)",
volume = "19",
journal = "Respiratory research",
issn = "1465-9921",
publisher = "BioMed Central",
number = "1",
}